Ann: Appendix 4C - quarterly, page-5

Sight of relief, these costs for GBM are very modest and importantly have been made, last quarter. Still nearly 9m despite one off payments made last quarter.

GBM Agile payments have been made....so confirmation of KZA in that major trial soon.

________________
"The company would also highlight that, while G&A expenses are incurred fairly evenly throughout the year, cash invested in research and development activities tends to vary considerably by quarter. In particular, the cashflows reported in this Appendix 4C include milestone payments associated with the completion of the Cantrixil phase I study, as well as one-off costs for the set-up of GBM AGILE. Accordingly, it is difficult to draw inferences as to the anticipated expenditure in FY2021"

-----
This is exactly what the FDA boss was referring to on GBM Cancer day- top notch science like this, can be the perquisite of early approvals.


Dr Wen and Dr Ellingsons studies strongly featured -

"Taken together, these papers substantially reinforce the body of published scientific data for paxalisib and provide new insights into its mechanism of action and potential clinical efficacy'
________________________________

Up 15% in the US maybe.